MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis.

Cabo Beltran, Olga Rodriguez

MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis. [electronic resource] - Head & neck 03 2019 - 657-665 p. digital

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

1097-0347

10.1002/hed.25477 doi


Adolescent
Adult
Aged
Child
Child, Preschool
Female
Follow-Up Studies
Humans
Laryngoscopy
Male
Middle Aged
Papillomavirus Infections--pathology
Respiratory Tract Infections--pathology
Survival Analysis
Treatment Outcome
Vaccines, DNA
Viral Vaccines
Young Adult